Satisfactory treatment response is rarely achieved using current treatment options, little is known about the potential benefit of the PDE4 inhibitor apremilast in the treatment of refractory PPPP patients. The gene discussed is PDE4A; the disease is punctate palmoplantar keratoderma type 2.